Core Viewpoint - LivaNova (LIVN) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Recent Performance and Projections - LivaNova is projected to earn $3.37 per share for the fiscal year ending December 2024, reflecting a year-over-year increase of 20.4% [8]. - Over the past three months, the Zacks Consensus Estimate for LivaNova has risen by 10.3%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - LivaNova's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

LivaNova (LIVN) closed the last trading session at $52.10, gaining 0% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72 indicates a 38.2% upside potential.The mean estimate comprises nine short-term price targets with a standard deviation of $8.15. While the lowest estimate of $61 indicates a 17.1% increase from the current price level, the most optimistic analyst expects the sto ...

Financial Performance - LivaNova reported a total revenue of $287.5 million for the quarter, reflecting a 10% increase year-over-year[2]. - The company achieved a gross margin of 65%, up from 62% in the previous year, indicating improved operational efficiency[2]. - LivaNova's Neuromodulation segment generated $150 million in revenue, representing a 15% growth compared to the same quarter last year[2]. - The Cardiopulmonary segment saw a revenue increase of 8%, totaling $137.5 million for the quarter[2]. - Net income for the nine months ended September 30, 2024, was $32,953,000, compared to a loss of $7,318,000 for the same period in 2023, representing a significant turnaround[13]. - Comprehensive income for the nine months ended September 30, 2024, was $59,069,000, compared to a loss of $26,540,000 in the prior year[13]. - Total revenue for the nine months ended September 30, 2024, reached $931.607 million, compared to $843.413 million for the same period in 2023, reflecting an increase of 10.4%[78]. - Operating income for the three months ended September 30, 2024, was $35.618 million, compared to $4.458 million in Q3 2023, indicating a substantial improvement in profitability[80]. - Basic earnings per share for Q3 2024 was $0.61, compared to a loss of $0.14 in Q3 2023, while diluted earnings per share was $0.60 versus a loss of $0.14 in the same period[10][76]. Cash and Assets - Cash and cash equivalents increased to $346,366,000 as of September 30, 2024, from $266,504,000 at the end of 2023, reflecting a growth of 30%[14]. - Total assets rose to $2,521,958,000 as of September 30, 2024, compared to $2,429,563,000 at the end of 2023, indicating an increase of approximately 3.8%[14]. - Total stockholders' equity increased to $1,310,044,000 as of September 30, 2024, from $1,277,628,000 at the end of 2023, showing a growth of 2.5%[15]. - Net cash provided by operating activities for the nine months ended September 30, 2024, was $104,331,000, significantly higher than $20,956,000 for the same period in 2023[16]. - Cash, cash equivalents, and restricted cash at the end of the period increased to $666.576 million as of September 30, 2024, compared to $532.722 million at the end of September 2023, marking an increase of approximately 25%[16]. Research and Development - LivaNova plans to invest $50 million in R&D for new product development in the next fiscal year[2]. - Research and development costs increased to $6.2 million as of September 30, 2024, from $2.5 million in the previous year[90]. - The company is focused on enhancing its core Cardiopulmonary and Neuromodulation segments as part of its restructuring plan initiated in early 2024[3]. Restructuring and Strategic Initiatives - The company has initiated a restructuring plan aimed at enhancing focus on its core segments, expected to yield $30 million in annual savings[2]. - LivaNova's restructuring plan aims to enhance focus on its core Cardiopulmonary and Neuromodulation segments by winding down the ACS segment[20]. - The company plans to discontinue operations for certain ACS products by the end of 2024 as part of its restructuring plan[77]. Debt and Financial Obligations - Long-term debt obligations increased to $604,287,000 as of September 30, 2024, from $568,543,000 at the end of 2023, reflecting a rise of 6.3%[14]. - The company issued $345.0 million of 2.50% notes due 2029, with net proceeds of $332.1 million after deducting issuance costs[47][48]. - The effective interest rate for the 2029 Notes is 9.79% as of September 30, 2024[48]. - The company has a revolving credit facility of $225.0 million, maturing on March 8, 2029, available for working capital[45]. Legal and Compliance Matters - The provision for product liability litigation increased to $19.2 million as of September 30, 2024, up from $13.9 million as of December 31, 2023, due to new claims information[58]. - The company is involved in various pending legal actions that may materially affect its financial position, but outcomes are uncertain[63]. - The company has not recognized a liability related to the environmental litigation as any potential loss is not currently probable[57]. Market Expansion and Future Outlook - The company is focusing on expanding its market presence in Europe and Asia, targeting a 20% market share increase by 2025[2]. - LivaNova's recent acquisition of ImThera Medical is projected to contribute an additional $25 million in revenue by 2025[2]. - The company has set a performance guidance of $1.2 billion in total revenue for the upcoming fiscal year, with an expected growth rate of 12%[2]. Cybersecurity Incident - LivaNova incurred direct costs of $10.8 million related to a cybersecurity incident, with $2.5 million and $8.2 million incurred during the three and nine months ended September 30, 2024, respectively[18]. - The company expects to incur additional costs related to the cybersecurity incident in the future, with insurance coverage likely insufficient to cover all expenses[18]. - A settlement related to a cybersecurity incident led to an accrual of $1.2 million during the quarter ended September 30, 2024[62].

LivaNova PLC (NASDAQ:LIVN) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Antho ...

| --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------| | | | | | | | Liva Nova Third-Quarter 2024 | | | | | | Earnings Update | | | | | | October 30, 2024 | | | | | Safe Harbor 2 Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements inc ...

LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 26.76%. A quarter ago, it was expected that this medical technology company would post earnings of $0.79 per share when it actually produced earnings of $0.93, delivering a surprise of 17.72%. Over the last four quarters, ...

EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Third-Quarter 2024 Results London, October 30, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. Financial Summary and Highlights (1) • Third-quarter revenue of $318.1 million increased 11.2% on both a reported and constant-currency basis, as compared to the prior-year period. Excluding the impact of the Advanced Circulatory Support (AC ...

If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab . We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some in ...

Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. There is high visibility into the company's near-term baseline growth, with potential upside to revenue and earnings from "new product cycles and pipeline optionality," according to Goldman Sachs. Analyst David Roman initiated coverage of LivaNova with a Buy rating and price target of $65. The LivaNova Thesis: LivaNova's earnings had been under pressure due to strategic shifts in the company's business and pipeline setbacks. Ro ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its char ...